REFERENCES 1. Lee EB, Amin M, Wu JJ. Drug survival of apremilast for psoriasis in a real-
world setting. J Am Acad Dermatol. 2018. https://doi. org/10.1016/. jaad. 2018.03. 028. 2 …

Baseline characteristics Female, n (%) 83 (63.3) 92 (54.8) 95 (58.6) 88 (53) 275 (55.3). 11
Mean age, y (SD) 57.5 (12) 51.4 (11.7) 50.5 (11.2) 49.9 (11.4) 50.6 (11.4) Mean duration of …

BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …

This real‐world study at a single academic center retrospectively examined the drug survival
of apremilast for patients with psoriasis. Retrospective information was extracted from the …

INTRODUCTION: Many options are available for patients with moderate to severe plaque
psoriasis. Patients with moderate disease, however, are often undertreated and do not …

Objectives To investigate the survival of apremilast in a cohort of psoriasis patients treated
with apremilast in a Greek hospital. Methods A retrospective cross-sectional study examined …

Objectives The aim of this paper is to present our personal as well as literature-sourced real-
world evidenced on apremilast use in psoriasis patients with serious baseline comorbidities …

Background: Apremilast 30 mg bid (APR) safety and tolerability were evaluated in patients
with moderate to severe plaque psoriasis (ESTEEM 1 and 2) or active psoriatic arthritis …

Apremilast has been approved as an effective and safe treatment for psoriasis, but clinical
trial results may differ from real‐life data. This retrospective cross‐sectional study evaluated …

DEAR EDITOR, Apremilast has demonstrated a favourable safety profile for the treatment of
psoriasis based on its pivotal randomized controlled trials (RCTs), ESTEEM 1 and 2. 1, 2 …